SRM Assay
SRM Assay
Development Services

Absolute Biomarker Quantitation by Mass Spectrometry

Development of Validated Absolute Quantitative Assays for Multi-protein Biomarker Panels

Modern proteomic biomarker discovery generally produces a panel of 5 - 50 candidates that require further qualification in a larger cohort of samples. In this context the biomarkers are usually tryptic peptides and replication studies often use antibodies against the parent protein. Selected Reaction Monitoring (SRM) is a multiplexed, targeted mass spectrometry assay format for the routine measurement of biomarkers that is particularly suited to monitoring candidates that do not have validated commercially available antibodies especially post-translational modifications. Our SRM assay development service produces bespoke assay panels with defined performance characteristics that are suitable for routine use in large study cohorts. Our expert team will guide you in the best workflow for your biomarker candidates, including selection of proteotypic peptides and optimization of sample preparation where appropriate.         

The SRM Assay Development Process:

 
Phase 1Selection of proteotypic peptides
Phase 2Ordering AQUA peptides (if required)
Phase 3SRM assay development and validation
Phase 4Optimization of sample preparation (if required)
Phase 5Biomarker qualification in small cohort
Phase 6Biomarker validation in larger cohort 

The SRM Assay Development Offers:

Assay Development Services Include

  • Selection of proteotyic peptides by our expert team, usually from empirical data
  • Ordering of AQUA peptides from our recommended supplier
  • TSQ Vantage Mass Spectrometry
  • Optimization of sample preparation workflow where appropriate.
  • Pre-determined sample collection, processing and shipment protocols
  • Comprehensive report including SRM method, assay performance characteristics and biomarker validation results

 

 

 

Case Studies

Turning Problems... Into Solutions

Clusterin Glycosylation – A Prognostic AD Plasma Biomarker
Clusterin Glycosylation – A Prognostic AD Plasma Biomarker
Product: SRM Assay Development
READ MORE
Characterization of Tau phosphorylation in Preclinical Models of AD
Characterization of Tau phosphorylation in Preclinical Models of AD
Product: SRM Assay Development
READ MORE
Stratification of Breast Tumors Based on ER, PR and HER2 Expression and Activity
Stratification of Breast Tumors Based on ER, PR and HER2 Expression and Activity
Product: SRM Assay Development
READ MORE
Have questions about SRM Assay Development Services?
To get more information about our SRM Assay Development Services or to arrange a consultation with our scientists regarding your Assay Development project.